Intermediate-high risk pulmonary embolism: When teamwork really matters

Q4 Medicine Thrombosis Update Pub Date : 2023-12-21 DOI:10.1016/j.tru.2023.100157
Bibi Ayesha Bassa , Elizabeth Little , Izak Loftus , Leah Flanagan , Andrew Neil , Tomás Breslin , Cian McDermott
{"title":"Intermediate-high risk pulmonary embolism: When teamwork really matters","authors":"Bibi Ayesha Bassa ,&nbsp;Elizabeth Little ,&nbsp;Izak Loftus ,&nbsp;Leah Flanagan ,&nbsp;Andrew Neil ,&nbsp;Tomás Breslin ,&nbsp;Cian McDermott","doi":"10.1016/j.tru.2023.100157","DOIUrl":null,"url":null,"abstract":"<div><p>Pulmonary embolism is a common disease associated with significant morbidity and mortality. Existing validated risk stratification tools have enabled the rapid identification of patients with low versus high-risk pulmonary embolism. Intermediate-high risk pulmonary embolism is defined as pulmonary embolism with haemodynamic stability, evidence of right ventricular dysfunction and elevated cardiac biomarkers. The therapeutic management of intermediate-high risk pulmonary embolism in the acute setting is challenging as these patients are often unwell, but do not fulfil criteria for high-risk pulmonary embolism. Although current guidelines recommend prompt first-line treatment with systemic anticoagulation and monitoring for deterioration, alternative strategies are being increasingly considered in this cohort. These include systemic or catheter-directed thrombolysis, surgical embolectomy, and mechanical circulatory support. In this case series, we discuss three cases of intermediate-high risk pulmonary embolism with a focus on multidisciplinary decision making in clinical management. Following on from this, we provide a brief narrative review of the current literature and guidelines surrounding this topic, considering the risks and benefits of alternative therapy options on patient outcomes.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572723000287/pdfft?md5=fbf25e90a59089099db2532c45a0e508&pid=1-s2.0-S2666572723000287-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572723000287","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Pulmonary embolism is a common disease associated with significant morbidity and mortality. Existing validated risk stratification tools have enabled the rapid identification of patients with low versus high-risk pulmonary embolism. Intermediate-high risk pulmonary embolism is defined as pulmonary embolism with haemodynamic stability, evidence of right ventricular dysfunction and elevated cardiac biomarkers. The therapeutic management of intermediate-high risk pulmonary embolism in the acute setting is challenging as these patients are often unwell, but do not fulfil criteria for high-risk pulmonary embolism. Although current guidelines recommend prompt first-line treatment with systemic anticoagulation and monitoring for deterioration, alternative strategies are being increasingly considered in this cohort. These include systemic or catheter-directed thrombolysis, surgical embolectomy, and mechanical circulatory support. In this case series, we discuss three cases of intermediate-high risk pulmonary embolism with a focus on multidisciplinary decision making in clinical management. Following on from this, we provide a brief narrative review of the current literature and guidelines surrounding this topic, considering the risks and benefits of alternative therapy options on patient outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中高风险肺栓塞:团队合作真的很重要
肺栓塞是一种常见疾病,发病率和死亡率都很高。现有的有效风险分层工具能够快速识别低危和高危肺栓塞患者。中高风险肺栓塞被定义为血流动力学稳定、有右心室功能障碍和心脏生物标志物升高证据的肺栓塞。急性期中高风险肺栓塞的治疗管理具有挑战性,因为这些患者通常身体不适,但不符合高风险肺栓塞的标准。尽管目前的指南建议及时进行全身抗凝一线治疗并监测病情恶化,但越来越多的人开始考虑对这类患者采取其他治疗策略。这些策略包括全身或导管引导溶栓、外科栓子切除术和机械循环支持。在本病例系列中,我们讨论了三例中高危肺栓塞病例,重点是临床管理中的多学科决策。在此基础上,我们简要回顾了围绕这一主题的现有文献和指南,并考虑了替代疗法对患者预后的风险和益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Thrombosis Update
Thrombosis Update Medicine-Hematology
CiteScore
1.90
自引率
0.00%
发文量
33
审稿时长
86 days
期刊最新文献
Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO) Usability study of the qLabs® FIB: A new point-of-care system for functional fibrinogen testing Nitrous oxide and VTE – no laughing matter Practical model for implementation of cancer-associated thrombosis prevention in the outpatient setting
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1